Abstract
BACKGROUND This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal cell carcinoma (nccRCC). In addition, the survival outcome of metastatic nccRCC patients was characterized. METHODS Data on 2215 patients (1963 with clear-cell RCC [ccRCC] and 252 with nccRCC) treated with first-line VEGF- and mTOR-targeted therapies were collected from the IMDC. Time to treatment failure (TTF) and overall survival (OS) were compared in groups with favorable, intermediate, and poor prognoses according to IMDC prognostic criteria RESULTS The median OS of the entire cohort was 20.9 months. nccRCC patients were younger (P <.0001) and more often presented with low hemoglobin (P =.014) and elevated neutrophils (P =.0001), but otherwise had clinicopathological features similar to those of ccRCC patients. OS (12.8 vs 22.3 months; P <.0001) and TTF (4.2 vs 7.8 months; P <.0001) were worse in nccRCC patients compared with ccRCC patients. The hazard ratio for death and TTF when adjusted for the prognostic factors was 1.41 (95% CI, 1.19-1.67; P <.0001) and 1.54 (95% CI, 1.33-1.79; P <.0001), respectively. The IMDC prognostic model reliably discriminated 3 risk groups to predict OS and TTF in nccRCC; the median OS of the favorable, intermediate, and poor prognosis groups was 31.4, 16.1, and 5.1 months, respectively (P <.0001), and the median TTF was 9.6, 4.9, and 2.1 months, respectively (P <.0001). CONCLUSIONS Although targeted agents have significantly improved the outcome of patients with nccRCC, for the majority survival is still inferior compared with patients with ccRCC. The IMDC prognostic model reliably predicts OS and TTF in nccRCC and ccRCC patients.
| Original language | English |
|---|---|
| Pages (from-to) | 2999-3006 |
| Number of pages | 8 |
| Journal | Cancer |
| Volume | 119 |
| Issue number | 16 |
| DOIs | |
| Publication status | Published - 2013 May 28 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
}
Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents : Characterization of survival outcome and application of the International mRCC Database Consortium criteria. / Kroeger, Nils; Xie, Wanling; Lee, Jae Lyn; Bjarnason, Georg A.; Knox, Jennifer J.; MacKenzie, Mary J.; Wood, Lori; Srinivas, Sandy; Vaishamayan, Ulka N.; Rha, Sun Young; Pal, Sumanta K.; Yuasa, Takeshi; Donskov, Frede; Agarwal, Neeraj; Kollmannsberger, Christian K.; Tan, Min Han; North, Scott A.; Rini, Brian I.; Choueiri, Toni K.; Heng, Daniel Y.C.
In: Cancer, Vol. 119, No. 16, 28.05.2013, p. 2999-3006.Research output: Contribution to journal › Article
TY - JOUR
T1 - Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents
T2 - Characterization of survival outcome and application of the International mRCC Database Consortium criteria
AU - Kroeger, Nils
AU - Xie, Wanling
AU - Lee, Jae Lyn
AU - Bjarnason, Georg A.
AU - Knox, Jennifer J.
AU - MacKenzie, Mary J.
AU - Wood, Lori
AU - Srinivas, Sandy
AU - Vaishamayan, Ulka N.
AU - Rha, Sun Young
AU - Pal, Sumanta K.
AU - Yuasa, Takeshi
AU - Donskov, Frede
AU - Agarwal, Neeraj
AU - Kollmannsberger, Christian K.
AU - Tan, Min Han
AU - North, Scott A.
AU - Rini, Brian I.
AU - Choueiri, Toni K.
AU - Heng, Daniel Y.C.
PY - 2013/5/28
Y1 - 2013/5/28
N2 - BACKGROUND This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal cell carcinoma (nccRCC). In addition, the survival outcome of metastatic nccRCC patients was characterized. METHODS Data on 2215 patients (1963 with clear-cell RCC [ccRCC] and 252 with nccRCC) treated with first-line VEGF- and mTOR-targeted therapies were collected from the IMDC. Time to treatment failure (TTF) and overall survival (OS) were compared in groups with favorable, intermediate, and poor prognoses according to IMDC prognostic criteria RESULTS The median OS of the entire cohort was 20.9 months. nccRCC patients were younger (P <.0001) and more often presented with low hemoglobin (P =.014) and elevated neutrophils (P =.0001), but otherwise had clinicopathological features similar to those of ccRCC patients. OS (12.8 vs 22.3 months; P <.0001) and TTF (4.2 vs 7.8 months; P <.0001) were worse in nccRCC patients compared with ccRCC patients. The hazard ratio for death and TTF when adjusted for the prognostic factors was 1.41 (95% CI, 1.19-1.67; P <.0001) and 1.54 (95% CI, 1.33-1.79; P <.0001), respectively. The IMDC prognostic model reliably discriminated 3 risk groups to predict OS and TTF in nccRCC; the median OS of the favorable, intermediate, and poor prognosis groups was 31.4, 16.1, and 5.1 months, respectively (P <.0001), and the median TTF was 9.6, 4.9, and 2.1 months, respectively (P <.0001). CONCLUSIONS Although targeted agents have significantly improved the outcome of patients with nccRCC, for the majority survival is still inferior compared with patients with ccRCC. The IMDC prognostic model reliably predicts OS and TTF in nccRCC and ccRCC patients.
AB - BACKGROUND This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal cell carcinoma (nccRCC). In addition, the survival outcome of metastatic nccRCC patients was characterized. METHODS Data on 2215 patients (1963 with clear-cell RCC [ccRCC] and 252 with nccRCC) treated with first-line VEGF- and mTOR-targeted therapies were collected from the IMDC. Time to treatment failure (TTF) and overall survival (OS) were compared in groups with favorable, intermediate, and poor prognoses according to IMDC prognostic criteria RESULTS The median OS of the entire cohort was 20.9 months. nccRCC patients were younger (P <.0001) and more often presented with low hemoglobin (P =.014) and elevated neutrophils (P =.0001), but otherwise had clinicopathological features similar to those of ccRCC patients. OS (12.8 vs 22.3 months; P <.0001) and TTF (4.2 vs 7.8 months; P <.0001) were worse in nccRCC patients compared with ccRCC patients. The hazard ratio for death and TTF when adjusted for the prognostic factors was 1.41 (95% CI, 1.19-1.67; P <.0001) and 1.54 (95% CI, 1.33-1.79; P <.0001), respectively. The IMDC prognostic model reliably discriminated 3 risk groups to predict OS and TTF in nccRCC; the median OS of the favorable, intermediate, and poor prognosis groups was 31.4, 16.1, and 5.1 months, respectively (P <.0001), and the median TTF was 9.6, 4.9, and 2.1 months, respectively (P <.0001). CONCLUSIONS Although targeted agents have significantly improved the outcome of patients with nccRCC, for the majority survival is still inferior compared with patients with ccRCC. The IMDC prognostic model reliably predicts OS and TTF in nccRCC and ccRCC patients.
UR - http://www.scopus.com/inward/record.url?scp=84881480218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881480218&partnerID=8YFLogxK
U2 - 10.1002/cncr.28151
DO - 10.1002/cncr.28151
M3 - Article
C2 - 23696129
AN - SCOPUS:84881480218
VL - 119
SP - 2999
EP - 3006
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 16
ER -